Terms: = Prostate cancer AND FANCA, MGC75158, 2175, ENSG00000187741, FA-H, FA, FAA, FANCH, FA1, FACA AND Treatment
55 results:
1. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract] [Full Text] [Related]
2. Physicochemical and Biopharmaceutical Controllability of New Self-Assembled Fatty Acid Conjugated Leuprolide for the Enhanced Anticancer Activity.
Ngo HV; Bak HE; Nguyen HD; Lee KW; Park C; Lee BJ
Int J Nanomedicine; 2023; 18():2325-2344. PubMed ID: 37168738
[TBL] [Abstract] [Full Text] [Related]
3. In vitro and in vivo Evaluation of Folic Acid Modified DOX-Loaded
Deng H; Wang Y; Zhou Y; Zhai D; Chen J; Hao S; Chen X
Int J Nanomedicine; 2023; 18():2003-2015. PubMed ID: 37077940
[TBL] [Abstract] [Full Text] [Related]
4. Evaluating Germline Testing Panels in Southern African Males With Advanced prostate cancer.
Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
[TBL] [Abstract] [Full Text] [Related]
5. Targeted PEGylated Chitosan Nano-complex for Delivery of Sodium Butyrate to prostate cancer: An In Vitro Study.
Zamanvaziri A; Meshkat M; Alazmani S; Khaleghi S; Hashemi M
Technol Cancer Res Treat; 2023; 22():15330338231159223. PubMed ID: 36855824
[No Abstract] [Full Text] [Related]
6. VMAT partial arc technique decreases dose to organs at risk in whole pelvic radiotherapy for prostate cancer when compared to full arc VMAT and IMRT.
Bartlett GK; Njeh CF; Huang KC; DesRosiers C; Guo G
Med Dosim; 2023 Spring; 48(1):8-15. PubMed ID: 36319515
[TBL] [Abstract] [Full Text] [Related]
7. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with fanca mutation: A case report.
Lai YH; Tung KC; Chen SC
Medicine (Baltimore); 2022 Sep; 101(39):e30719. PubMed ID: 36181052
[TBL] [Abstract] [Full Text] [Related]
8. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic prostate cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract] [Full Text] [Related]
9. Progress in the drug encapsulation of poly(lactic-
Dodda JM; Remiš T; Rotimi S; Yeh YC
J Mater Chem B; 2022 Jun; 10(22):4127-4141. PubMed ID: 35593381
[TBL] [Abstract] [Full Text] [Related]
10. Foliate-Targeting Quantum Dots-
Pilch J; Kowalik P; Kowalczyk A; Bujak P; Kasprzak A; Paluszkiewicz E; Augustin E; Nowicka AM
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163186
[TBL] [Abstract] [Full Text] [Related]
11. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract] [Full Text] [Related]
12. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Shore N; Ionescu-Ittu R; Yang L; Laliberté F; Mahendran M; Lejeune D; Yu L; Burgents J; Duh MS; Ghate SR
Future Oncol; 2021 Aug; 17(22):2907-2921. PubMed ID: 33906368
[TBL] [Abstract] [Full Text] [Related]
13. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
[TBL] [Abstract] [Full Text] [Related]
14. An effective strategy for development of docetaxel encapsulated gold nanoformulations for treatment of prostate cancer.
Thambiraj S; Vijayalakshmi R; Ravi Shankaran D
Sci Rep; 2021 Feb; 11(1):2808. PubMed ID: 33531521
[TBL] [Abstract] [Full Text] [Related]
15. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of a Mainstream Model of Genetic Testing for Men With prostate cancer.
Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath LG
JCO Oncol Pract; 2021 Feb; 17(2):e204-e216. PubMed ID: 32970524
[TBL] [Abstract] [Full Text] [Related]
17. When and How to Use PARP Inhibitors in prostate cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract] [Full Text] [Related]
18. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
19. Folic acid-modified methotrexate-conjugated gold nanoparticles as nano-sized trojans for drug delivery to folate receptor-positive cancer cells.
Yücel O; Şengelen A; Emik S; Önay-Uçar E; Arda N; Gürdağ G
Nanotechnology; 2020 Aug; 31(35):355101. PubMed ID: 32413875
[TBL] [Abstract] [Full Text] [Related]
20. Epidemiology and biological characteristics of male breast cancer in Italy.
Mangone L; Ferrari F; Mancuso P; Carrozzi G; Michiara M; Falcini F; Piffer S; Filiberti RA; Caldarella A; Vitale F; Tumino R; Brustolin A; Tagliabue G; Giorgi Rossi P; Ottini L
Breast Cancer; 2020 Jul; 27(4):724-731. PubMed ID: 32114665
[TBL] [Abstract] [Full Text] [Related]
[Next]
